Dare Bioscience, Inc. (DARE) analyst actions
Rating and price-target actions on DARE in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the DARE overview →
1 measured DARE analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies | Press release | +1.91% | +0.48% |
Keep exploring
More DARE: earnings → · SEC filings → · DARE overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| IKANG HEALTH CARE GROUP (KANG) | 242 | -0.07% | 44% |
| Adial Pharmaceuticals, Inc (ADIL) | 241 | 0.00% | 44% |
| Genprex, Inc. (GNPX) | 241 | -1.17% | 33% |
| Allakos Inc. (ALLK) | 240 | -0.70% | 35% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.